US equities |
META $620.19 ▼-1.64% MU $928.76 ▲+2.77% NVDA $217.94 ▲+0.90% TSLA $407.46 ▲+4.04% SPCX $148.58 ▲+1.14% AAPL $347.10 ▲+0.93% AMD $560.26 ▲+5.45% MSFT $531.33 ▼-0.24%
FinancialContent

Wave Life Sciences, Inc. - Common Stock (NQ:WVE)

3.450 +0.240 (+7.48%)
Delayed Quote Updated: 4:00 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Wave Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
The Analyst Verdict: WAVE Life Sciences In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year ↗
Wave Life plans a 2026 NDA filing for WVE-N531 after positive Phase 2 data in Duchenne muscular dystrophy, showing functional gains and biomarker improvements. 
Via Benzinga
News headline image
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
What's Next: WAVE Life Sciences's Earnings Preview ↗
 
Via Benzinga
News headline image
Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 4, 2025 ↗
 
Via Benzinga
News headline image
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences to Present at Upcoming Investor Conferences
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences to Present at Jefferies London Healthcare Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
1 Brand-New Big Reason to Buy This Biotech Stock Right Now ↗
This stock currently has a good balance of risk and potential rewards. 
Via The Motley Fool
News headline image
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space. ↗
Korro Bio is lagging Wave Life Sciences. But an analyst says it could ultimately be the leader. 
Via Investor's Business Daily
News headline image
Oklo, CleanSpark And Wolfspeed Are Among Top 7 Mid Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio? ↗
These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio? 
Via Benzinga
News headline image
Wave Life Sciences Rockets 70% on Historic RNA Editing Success
Wave Life Sciences' RNA editing advances have generated investor interest as the company strives to become a leading force in the treatment of genetic diseases. 
Via MarketBeat
News headline image
This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans ↗
Wave Life Sciences' WVE-006 demonstrates first-ever RNA editing in humans for alpha-1 antitrypsin deficiency, showing favorable safety and efficacy in early trial results. GSK holds global license... 
Via Benzinga
News headline image
Wave Life Sciences Just Edited RNA — And Shares Hit The Stratosphere ↗
The company is testing its new technology in patients with a genetic disease that impacts the lungs. 
Via Investor's Business Daily
News headline image
United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024
Event will highlight WVE-006 for AATD and Wave’s rapidly advancing, wholly owned pipeline of RNA medicines, including introducing new RNA editing programs and new preclinical data for WVE-007 INHBE... 
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >